Andrew J.YeeMD

Hematologic Oncology

Assistant Professor of Medicine, Harvard Medical School, Massachusetts General Hospital Cancer Center

Dr. Yee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Andrew J. Yee is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital and North Shore Medical Center. He is an Assistant Professor of Medicine at Harvard Medical School. He received his medical degree from Harvard Medical School and has been in practice 17 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007
Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000

PubMed

Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff
Leukemia & Lymphoma. 2024-12-01
1 citations
Functional Status and Quality of Life in Light-Chain Amyloidosis: Advanced Imaging, Longitudinal Changes, and Outcomes.
Olivier F Clerc, Shilpa Vijayakumar, Sarah A M Cuddy, Giada Bianchi, Jocelyn Canseco Neri
JACC. Heart Failure. 2024-12-01
An ATLAS to map MRD with peripheral blood.
Andrew J Yee
Blood. 2024-08-29

Lectures

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Analysis of Hospitalization and Readmissions after CAR T Cell Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all